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a b s t r a c t
Combinations of direct-acting antivirals (DAAs) against the hepatitis C virus (HCV) have the potential to
revolutionize the HCV therapeutic regime. An integral component of DAA combination therapies is HCV
NS5A inhibitors. It has previously been proposed that NS5A DAAs inhibit two functions of NS5A: RNA
replication and virion assembly. In this study, we characterize the impact of a prototype NS5A DAA,
daclatasvir (DCV), on HCV replication compartment formation. DCV impaired HCV replicase localization
and NS5A motility. In order to characterize the mechanism behind altered HCV replicase localization, we
examined the impact of DCV on the interaction of NS5A with its essential cellular cofactor,
phosphatidylinositol-4-kinase III α (PI4KA). We observed that DCV does not inhibit PI4KA directly, nor
does it impair early events of the NS5A–PI4KA interaction that can occur when NS5A is expressed alone.
NS5A functions that are unaffected by DCV include PI4KA binding, as determined by co-immunopre-
cipitation, and a basal accumulation of the PI4KA product, PI4P. However, DCV impairs late steps in
PI4KA activation that requires NS5A expressed in the context of the HCV polyprotein. These NS5A
functions include hyper-stimulation of PI4P levels and appropriate replication compartment formation.
The data are most consistent with a model wherein DCV inhibits conformational changes in the NS5A
protein or protein complex formations that occur in the context of HCV polyprotein expression and
stimulate PI4P hyper-accumulation and replication compartment formation.
& 2014 Elsevier Inc. All rights reserved.
Introduction
About 150 million people are chronically infected with hepatitis C
virus (HCV) (WHO). Therapy for HCV including interferon and
ribavarin and a viral protease inhibitor boceprevir or telapravir, is
successful in 75% of treatments (Chatel-Chaix et al., 2012). Recently,
simeprevir, another protease inhibitor and sofosbuvir, a nucleotide
analog inhibitor of the viral polymerase were also approved for
therapy and improvement of response rates (Stedman, 2014). Many
interferon-free regimens combining different DAA classes are currently
in clinical trials (Au and Pockros, 2014). A common component of
these combination therapies is the NS5A DAA, typiﬁed by the lead
compound daclatasvir (DCV). DCV has currently moved to Phase III
trials and is noteworthy due to its very high potency (picomolar)
against HCV in vitro as compared with other HCV inhibitors (Gao et al.,
2010). The mechanism of action for this drug class is unclear; however,
it is thought to target HCV NS5A since drug resistant mutations
accumulate in the viral NS5A gene (Lemm et al., 2010). NS5A DAAs
block HCV at two different stages of life cycle with distinct kinetics:
HCV replication complex formation and assembly of infectious HCV
particles (McGivern et al., 2014; Guedj et al., 2013).
NS5A is a multi-functional protein with roles in HCV replication
and virion assembly (Appel et al., 2008; Penin et al., 2004; Lohmann
et al., 2003; Blight et al., 2000). It binds RNA and interacts with
several cellular factors to establish an environment conducive for
virus replication (Moradpour and Penin, 2013; He et al., 2006). Two
phosphorylated forms of NS5A, a basally phosphorylated p56 form
and a hyper-phosphorylated form p58, exist in infected cells (Kaneko
et al., 1994). It has been suggested that the ratio between these two
forms is crucial for both replication and assembly of the virus (Evans
et al., 2004; Huang et al., 2007). HCV replicon cells treated with DCV
have reduced hyper-phosphorylated NS5A (Lemm et al., 2010; Qiu
et al., 2011). It is unclear whether this loss of hyper-phosphorylated
NS5A is due to the direct inhibition of a kinase that phosphorylates
NS5A or is due to an indirect effect mediated by the inhibition of HCV
replication. In addition to the lack of hyper-phosphorylated NS5A,
DCV-treated cells also show altered sub-cellular localization of NS5A
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but the mechanism of this mislocalization is unknown (Lee et al.,
2011; Targett-Adams et al., 2011).
One major function of NS5A is to recruit and activate the cellular
kinase phosphatidylinositol-4-kinase alpha (PI4KA) (Reiss et al.,
2011; Berger et al., 2011; Tai and Salloum, 2011 ; Bianco et al.,
2012; Reiss et al., 2013). PI4KA and potentially its product
phosphatidylinositol-4-phosphate (PI4P) are critical for HCV replica-
tion (Berger et al., 2009; Tai et al., 2009; Li et al., 2009; Borawski
et al., 2009; Trotard et al., 2009; Vaillancourt et al., 2009; Berger and
Randall, 2009). In the absence of PI4KA, non-structural proteins
form enlarged cytoplasmic structures suggesting improper forma-
tion of replication compartments (Reiss et al., 2011; Berger et al.,
2011; Tai and Salloum, 2011; Wang et al., 2014). Interestingly, we
observed a similar phenotype in DCV-treated cells, leading to the
hypothesis that DCVmay be altering NS5A–PI4KA interaction and/or
activation. To test this hypothesis, we relied on a Tet-inducible
osteosarcoma cell line (UHCV) that expresses full-length viral
proteins independent of replication (Moradpour et al., 1998). We
have previously reported that sole expression of NS5A in this system
weakly induces PI4P accumulation, while PI4P is highly induced in
the context of the HCV polyprotein (Berger et al., 2011). This
observation is consistent with the recent data that NS5B in addition
to NS5A is required to observe maximally elevated levels of PI4P in
cells (Reiss et al., 2013). In this study, we present evidence that DCV
blocks replicase formation and the hyper-induction of PI4P by the
HCV polyprotein, but not basal activation of PI4KA by NS5A alone.
These data lead to a model wherein NS5A alone can bind and
weakly activate the kinase in the presence of DCV, but that DCV
inhibits an NS5A conformational change that occurs in the context of
the HCV polyprotein and is associated with both PI4P hyper-
accumulation and HCV replication complex formation.
Results
Daclatasvir treatment results in large replicase protein structures
with morphology similar to those in cells treated with PI4KA siRNAs
DCV has been shown to cause NS5A relocalization (Lee et al.,
2011; Targett-Adams et al., 2011). To determine if other non-
structural proteins also relocalize in the presence of DCV, we used
cells that express HCV polyprotein independent of replication to
monitor replication compartment formation. U2OS osteosarcoma
cells expressing full-length HCV polyprotein under tetracycline-
inducible conditions (UHCV cells) have been previously used to
identify and describe the formation of HCV replication compart-
ments, the membranous web (Moradpour et al., 1998; Gosert et al.,
2003). UHCV cells were induced for HCV polyprotein expression in
the presence of DMSO or DCV (250 pM), then probed for NS5A and
NS5B (the polymerase) localization in UHCV (Fig. 1) In DMSO-
treated cells, NS5B shows evenly distributed reticular pattern as
observed previously (Berger et al., 2011). However, in DCV-treated
cells, NS5B forms large aggregated structures that co-localize with
NS5A. PI4KA siRNA-treatment of cells leads to similar aggregation
of replicase proteins and alters membranous web morphology
(Reiss et al., 2011; Berger et al., 2011; Tai and Salloum, 2011). The
similar phenotypes observed between PI4KA siRNA-treated cells
and DCV-treated cells lead to a hypothesis of parallel mechanism
of action, whereby DCV may perturb HCV-stimulated PI4P
accumulation.
Daclatasvir reduces NS5A motility and increases NS5A puncta
intensity
To better understand the nature of the large NS5A puncta, we
examined the effects of DCV on NS5A dynamics in HCV-infected
cells. NS5A has been reported to have two dynamic patterns
consisting of smaller motile structures and larger, less motile
structures (Eyre et al., 2014; Wolk et al., 2008). We constructed
an HCV JC1-like virus (NS2/3) with an eYFP insertion in the C-
terminal domain of NS5A, termed NS2/3 5A-eYFP similar to what
has been previously described (Moradpour et al., 2004). For
efﬁcient replication, residues 2242–2266 in NS5A domain II were
deleted (NS2/3 5AΔ25-eYFP) (Fig. 2A) (Gottwein et al., 2011). This
virus replicated similar to wild type HCV and was sensitive to DCV
treatment (Fig. 2B). We next performed live-cell imaging of NS2/3
5 AΔ25-eYFP infected cells that were treated with DCV or DMSO
and imaged after 3, 8 or 24 h (Movies S1–S4). The total distance
traveled (including progressive and non-progressive movement)
by NS5A puncta over 15 min periods was quantiﬁed. Three
representative particle tracks for DMSO and 24 h post DCV treat-
ment are shown in Fig. 2C. As quantiﬁed in Fig. 2D, by 8 h post DCV
treatment, the total distance traveled by NS5A puncta is reduced
and by 24 h, it is signiﬁcantly lower as compared to the DMSO
control. There was a signiﬁcant increase in the NS5A ﬂuorescence
intensities by 24 h post DCV treatment, consistent with the
kinetics of replicase aggregation observed in Fig. 1 (Fig. 2E). It
should be noted however that the increase in NS5A ﬂuorescent
intensities is not due to increase in protein levels but rather due to
aggregation of NS5A ﬂuorescent signal. Indeed, as expected,
steady-state NS5A levels are decreased upon DCV treatment due
to the inhibition of replication (Fig. 2F).
Daclatasvir inhibits HCV-induced PI4P accumulation
The aggregation of non-structural proteins in the presence of
DCV is similar to that observed in cells treated with siRNAs against
PI4KA, suggesting that DCV might be altering the NS5A–PI4KA
interaction. To determine whether DCV inhibits NS5A-mediated
PI4P accumulation, we induced UHCV cells for polyprotein expres-
sion and treated them simultaneously with either DMSO or DCV
for 72 h. As seen in Fig. 3A, uninduced UHCV cells show PI4P
localization restricted to Golgi, as indicated by colocalization of
PI4P with the Golgi marker GM130. Upon HCV polyprotein induc-
tion, greater that 80% of cells have PI4P accumulation away from
Golgi (Fig. 3B), as previously described (Berger et al., 2011).
However, when cells were treated with DCV during polyprotein
synthesis, PI4P intensity is signiﬁcantly reduced (Fig. 3C) and only
about 15% of cells showed PI4P relocalization away from Golgi
(Fig. 3B). This lack of HCV-mediated PI4P synthesis in DCV-treated
cells is not due to the decreased polyprotein expression. Although
DCV treatment altered NS5A localization, as in Figs. 1 and 3D,
similar levels of NS5A are observed in both DMSO and DCV-treated
Fig. 1. DCV causes aggregation of replicase proteins. UHCV cells were induced and
treated with DMSO or DCV (250 pM) for 72 h and probed for NS5B (red) and NS5A
(green). Note the aggregated staining of both NS5A and NS5B in DCV-treated cells.
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cells as analyzed by Western blot (Fig. 3E). Altogether, these data
suggest that DCV inhibits HCV-mediated PI4P hyper-induction and
relocalization.
Daclatasvir does not alter plasma membrane PI4P levels and is thus
unlikely to inhibit PI4KA directly
PI4KA is required to maintain plasma membrane pools of PI4P
(Balla et al., 2005). To determine whether DCV inhibits PI4KA
directly, we analyzed plasma membrane PI4P levels as described in
materials and methods, using distinct permeabilization conditions
from that used in Fig. 3 to visualize intracellular PI4P levels.
UHCV cells were induced or left uninduced for 72 h and
treated with DMSO (72 h), DCV (72 h) or the general PI kinase
inhibitor wortmannin (30 min) prior to probing for plasma
membrane pools of PI4P. As seen in Fig. 4A, there is signiﬁcant
staining of plasma membrane with the PI4P antibody in both
induced and uninduced cells, which is different from the intracel-
lular Golgi localization observed in Fig. 3. PI4P colocalizes to some
extent with wheat-germ agglutinin, which binds to lectins and
acts as a marker for the plasma membrane. There is however no
signiﬁcant difference between plasma membrane intensity of PI4P
in DMSO and DCV-treated cells, whereas plasma membrane
intensity of PI4P is signiﬁcantly diminished in cells treated with
wortmannin at a concentration (10 mM) that is known to inhibit
PI4KA (Fig. 4A and B). Altogether, these data suggest that DCV does
not block PI4KA activity directly but may block activation of PI4KA
by NS5 A.
Daclatasvir does not inhibit PI4P relocalization mediated by NS5A
alone
Given that DCV prevented PI4P hyper-accumulation in cells
expressing full-length HCV polyprotein, we next examined
whether DCV impacts the modestly enhanced stimulation of
PI4P accumulation observed in cells expressing NS5A alone
(Reiss et al., 2011; Berger et al., 2011). Induction of NS5A in UNS5A
cells moderately stimulates PI4P accumulation (1.5-fold, Fig. 5A
Fig. 2. DCV causes reduction in NS5A movement and an increase in NS5A intensity. (A) Schematic of WT, NS5A deletion and NS5A-eYFP NS2/3 constructs (shaded structural
region is from J6 genotype while the non-structural regions are from JFH1 genotype). (B) Huh-7.5 cells were electroporated with in vitro transcribed RNA from the constructs
described in panel A. and either DMSO or DCV (1 nM) was added to cells at 4 h post-electroporation (hpe). RNA was collected at 4, 24, 48, 72, and 96 hpe and analyzed by
quantitative RT-PCR, normalizing to RNA levels at 4hpe. (C–E) Huh-7.5 cells were infected with NS2/3 NS5AΔ25-eYFP virus. 48 post-infection (hpi), cells were treated with
DMSO or DCV (500 pM) and monitored at 3, 8 and 24 h post-treatment using confocal microscopy. Images were taken every 20 s for a total of 15 min. (C) Representative
tracks of 3 particles for DMSO and DCV-treated cells are shown. (D) Total distance traveled by NS5A-YFP puncta was calculated using Image J multi-tracker plugin. Each dot
represents the total distance traveled by individual puncta. (E) NS5A puncta intensity (integrated density) was calculated by using Manual multiple ROI analysis. ns, not
signiﬁcant; npo0.05; nnnpo0.001; nnnnpo0.0001. (F) Cells were treated as in C and cell-lysate was run on SDS-PAGE and blotted for NS5A and Actin.
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and C), albeit not as efﬁciently as observed in UHCV cells (6-fold,
Fig. 3A and C), even though, similar or more NS5 A is expressed in
the conditions tested (Fig. 3E. versus Fig. 5E.). This data suggests
that other HCV proteins may also have a role in modulating PI4P
accumulation, either directly or indirectly. When NS5A is
expressed alone, PI4P relocalization away from the Golgi (as seen
in line intensity plots) is similar in DMSO- and DCV-treated cells
suggesting that DCV is unable to block the initial PI4P relocaliza-
tion mediated by NS5A (Fig. 5A). The number of cells showing PI4P
relocalization is also not signiﬁcantly different between DMSO and
DCV-treated conditions (Fig. 5B). In contrast to UHCV cells, no
difference in NS5A localization was observed in UNS5A cells in the
presence of DCV (Fig. 5D). Steady state NS5A levels are also similar
in DMSO- and DCV-treated cells (Fig. 5E).
Biotinylated NS5A inhibitor interacts with NS5A at similar efﬁciency
in both UHCV and UNS5A cells
A biotinylated DCV-like drug has been used before for NS5A
interaction studies and the structural comparison between DCV and
Fig. 3. DCV prevents HCV polyprotein-mediated PI4P production. (A) UHCV cells were induced for HCV polyprotein synthesis or uninduced for 72 h and then were treated
with DMSO or DCV (250 pM) during the induction time. Cells were then ﬁxed and probed for PI4P (red) and GM130 (green). Image J color intensity plots for the white line
drawn in the merge image are shown on the right. (B) Quantiﬁcation of cells showing relocalization in each condition from three independent experiments is shown on the
bottom panel (n¼15 ﬁelds ranging from 40 to 60 cells/condition/experiment). Cells with more than 5 PI4P puncta above threshold signal away from Golgi (based on GM130
signal) were quantiﬁed as positive for relocalization. Error bars represent standard deviation between three independent experiments. (C) PI4P intensity levels per cell were
calculated using Image J. (D) Cells were treated as above and detected using indirect immunoﬂuorescence via sequential staining ﬁrst for NS5A (green) and then for PI4P
(red). (E) Cells were treated as in A and cell-lysate was run on SDS-PAGE and blotted for NS5A and Actin. nnnnpo0.0001.
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the tagged NS5A inhibitor is shown (Fig. 6A) (Gao et al., 2010).
Though not as potent inhibitor as DCV, this tagged NS5A inhibitor
still inhibits HCV replication (Fig. 6B). To determine whether the drug
binds NS5A expressed from both UHCV and UNS5A cells, a biotin-
tagged NS5A inhibitor was incubated with induced or uninduced
cells for 16 h before lysis. The biotinylated drug was then pulled
down with streptavidin beads overnight, washed and analyzed for
NS5A that was pulled down using western blotting. As seen in
Fig. 6C, the biotinylated drug precipitates NS5A at similar efﬁciency
in both UHCV and UNS5A cells. Thus, the inability to block PI4P
relocalization is not due to the inability of the drug to interact with
NS5A in UNS5A cells. Based on these data, it is likely that DCV does
not inhibit moderate PI4KA stimulation seen in cells expressing NS5A
alone but inhibits hyper-accumulation of PI4P observed only in the
context of HCV polyprotein expression.
Daclatasvir functions after NS5A–PI4KA interaction
In order to further analyze the mechanism by which DCV
inhibits PI4P production in UHCV cells, we tested whether NS5A
and PI4KA still interact in the presence of DCV. UHCV cells were
transduced with lentiviral pseudoparticles expressing HA-tagged
PI4KA and twenty-four hours later, cells were stimulated for HCV
protein expression. Cells were then treated for 24 h with DMSO or
DCV (250 pM) on day 3 and lysed and immunoprecipitated either
using HA or NS5A antibody. NS5A co-immunoprecipitated with
PI4KA and vice versa in DMSO-treated cells as previously
described (Fig. 7). PI4KA still co-immunoprecipitates with NS5A
in DCV-treated cells, suggesting that the interaction between NS5A
and PI4KA remains intact even in the presence of DCV. Similar
observations were made with endogenous PI4KA (data not
shown). Thus, it is likely that DCV functions subsequent to the
initial NS5A–PI4KA interaction (Fig. 6) and basal stimulation of
PI4KA activity (Fig. 5), but prior to the hyper-stimulation of PI4KA
(Figs. 1–3).
Daclatasvir resistant mutants rescue PI4P production
We next tested whether a DCV-resistant mutant could rescue
PI4P accumulation in DCV-treated cells. Huh-7.5 cells were
infected with either WT or DCV-resistant Y93H virus. Forty-eight
hours post-infection, cells were treated with DMSO (data not
shown) or 500 pM DCV and ﬁxed at 2, 6, and 24 h post-
treatment and probed for PI4P and NS5A (Fig. 8A and B). Cells
infected with WT virus showed signiﬁcant reduction in PI4P levels
starting at 6 h post DCV treatment. At around the same time, NS5A
begins to aggregate which is further increased by 24 h post-
treatment. This NS5A aggregation seems to correlate to what
was observed in DCV-treated UHCV cells (Fig. 1), live-cell analysis
(Fig. 2) and in siPI4KA-treated cells (Berger et al., 2011). The DCV-
resistant mutant Y93H-infected cells, on the other hand, had
enhanced PI4P accumulation in the presence of DCV and no
signiﬁcant difference was observed between the time points
(Fig. 8A and B). Similar to previous observations, this mutant also
rescues NS5A localization (Targett-Adams et al., 2011). Thus, the
drug-resistant mutant is able to rescue PI4P production in the
presence of DCV. Consistent with NS5A aggregation and loss of
PI4P levels that are indicative of replication inhibition, NS5A levels
were also reduced by 24 h in WT but not in the resistant Y93H
virus infected cells (Fig. 8C). Hyperphosphorylated NS5A
decreased with greater kinetics than hypophosphorylated NS5A
DCV treatment for WT virus (Fig. 8C). This suggests that either
DCV directly inhibits NS5A phosphorylation, or alternatively, that
hyperphosphorylated NS5A has a shorter half-life and hypopho-
sphorylated NS5A and that its preferential decrease is an indirect
effect of inhibiting HCV replication.
In order to verify the above data in replication-independent
mechanism, we switched to transient transfection of NS3-5b in
T7RP cells instead of using UHCV cells, since NS5A hyperphosphor-
ylation is not readily distinguished in UHCV cells. T7RP cells were
transfected with NS3-5B expression plasmid containing either WT,
DCV-resistant mutant Y93H or PI4KA-interaction mutant HIT-AAA of
NS5A. Four hours post-transfection, cells were treated with DMSO or
DCV (500 pM or 5 nM) and either ﬁxed or lysed at 24 h post-
transfection. Similar to UHCV and virus infection data, DCV inhibited
PI4P levels in WT NS5A expressing cells (Fig. 9A and B). The Y93H
mutant, on the other hand, did not show any signiﬁcant changes in
PI4P levels even with high concentrations of PI4P. The PI4KA-
interaction mutant, HIT-AAA, as expected did not show any increase
Fig. 4. DCV does not inhibit plasma membrane PI4P levels that are maintained by
PI4KA. UHCV cells were induced or uninduced for a total of 72 h. Cells were either
treated with DMSO or 250 pM DCV for 24 h or 10 mM wortmannin for 2 h, prior to
incubating with 50 mg/ml Alexa Fluor 488-Wheat Germ Agglutinin on ice for 5 min
to mark cell surface. Cells were then ﬁxed and stained for plasma membrane PI4P.
(A) Z-stack images across the plane of the cell were taken using confocal
microscope and the maximum intensity projection image is shown.
(B) Quantiﬁcation of PI4P intensity per cell is shown. Error bars represent standard
deviation between cells. ns, not signiﬁcant; npo0.05.
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in PI4P levels with or without DCV treatment. Surprisingly, hyper-
phosphorylation of NS5A was not affected in either the WT or Y93H
mutant upon DCV treatment (Fig. 9C and D). As was previously
shown, the HIT-AAA mutant had increased NS5A hyperphosphoryla-
tion (Reiss et al., 2013). Interestingly, DCV treatment decreased the
accumulation of NS5A hyper-phosphorylation in the NS5A HIT-AAA
mutant (Fig. 9C and D).
Discussion
Previously, we and others have shown that NS5 A interacts
with and stimulates PI4KA for efﬁcient replication (Reiss et al.,
2011; Berger et al., 2011; Tai and Salloum, 2011; Bianco et al.,
2012). Impairment of PI4KA function in HCV replication, either by
siRNAs or pharmacological inhibitors, perturbs HCV replication
Fig. 5. DCV does not prevent NS5A-mediated PI4P relocalization. (A) UNS5A cells were induced for HCV NS5A synthesis or uninduced for 92 h in the presence of DMSO or
DCV (250 pM). Cells were then ﬁxed and probed for PI4P (red) and GM130 (green) and analyzed as in Fig. 3A. Image J color intensity plots for the white line drawn in the
merge image are shown on the right. (B) Quantiﬁcation of cells showing relocalization in each condition from three independent experiments is shown on the bottom panel
(n¼15 ﬁelds ranging from 40 to 80 cells/condition/experiment). Cells with more than 5 PI4P puncta above threshold signal away from Golgi (based on GM130 signal) were
quantiﬁed as positive for relocalization. Error bars represent standard deviation between three independent experiments. (C) PI4P intensity levels per cell were calculated
using Image J and plotted. (D) Cells were treated as above and detected using indirect immunoﬂuorescence via sequential staining ﬁrst for NS5A (green) and then for PI4P
(red). (E) Cells were treated as in A and cell-lysate was run on SDS-PAGE and blotted for NS5A and Actin. nnnnpo0.0001; ns, not signiﬁcant.
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compartment formation. PI4KA inhibition aggregates the HCV
replicase, resulting in large clusters of double membrane vesicles
with reduced individual diameter. PI4KA appears to have multiple
functions in HCV replication. Its direct product, PI4P, functions in
recruiting cellular lipid transfer proteins to the HCV replication
compartment. In particular, the cholesterol transporter oxysterol-
binding protein (OSBP) binds PI4P, localizes to the HCV replication
compartment, and is required for optimal HCV replication (Wang
et al., 2014). Additionally, PI4KA modulates the phosphorylation
status of NS5 A, either directly or indirectly. In the absence of
PI4KA, there is an increased accumulation of hyperphosphorylated
NS5 A (Reiss et al., 2013).
In this study, we investigated the effect of DCV on NS5 A motility
and the NS5A–PI4KA interaction. Using both a genotype 1a polypro-
tein inducible system (UHCV) and genotype 2a infection, we show
evidence that PI4P accumulation is drastically reduced in DCV-treated
cells (Figs. 3 and 7). In addition, we show that in both systems, viral
replicase components aggregate during DCV treatment similar to what
was previously described in PI4KA knockdown cells (Figs. 1, 2 and 7)
(Reiss et al., 2011; Berger et al., 2011). The accumulation of NS5A into
large ﬂuorescent foci following DCV treatment is kinetically associated
with decreases in NS5A velocities (Fig. 2).
NS5A DAAs have been shown to affect some, but not all,
activities associated with NS5A. DCV impairs replication compart-
ment formation and virion assembly, but other functions, such as
RNA binding and dimerization, are largely unaffected (Lee et al.,
2011; Targett-Adams et al., 2011; Lim et al., 2012). Though it has
been recently suggested that NS5A inhibitors compete out oligos
for NS5A binding (Ascher et al., 2014), no such competition was
seen for HCV 30 UTR RNA sequence (Targett-Adams et al., 2011). In
this study, we deﬁne distinct NS5A–PI4KA interactions that
are both resistant and sensitive to DCV treatment. The initial
interactions of NS5A with PI4KA, including a physical interaction
as deﬁned by co-immunoprecipitation, and a modest stimulation
of PI4P accumulation away from the Golgi in cells expressing
NS5A alone are largely resistant to DCV inhibition. In contrast,
later functions associated with the NS5A–PI4KA interaction,
including hyper-accumulation of PI4P and appropriate replication
compartment formation are inhibited by DCV. Interestingly, the
latter DCV-inhibited NS5A functions require NS5A expression
to be in the context of the HCV polyprotein. This suggests either
that additional HCV proteins are directly involved in the modula-
tion of PI4KA by NS5A or alternatively, that NS5A achieves a
certain protein conformation only in the context of other HCV
proteins.
An alternative interpretation is that DCV might inhibit other
NS5A functions associated with maintaining PI4P pools, such as
binding ArfGAP1, which was reported to inﬂuence PI4P levels by
removing the lipid phosphatase Sac1 from replication compart-
ments (Li et al., 2014). The ArfGAP1 inhibitor, QS11, inhibits HCV
replication and reduces the level of PI4P in NS5A expressing cells.
This experiment is somewhat difﬁcult to interpret, however, as
NS5A alone is less efﬁcient in stimulating PI4P production com-
pared to full-length HCV polyprotein. We examined QS11 and
conﬁrmed that it inhibits HCV replication (Fig. S2C). However, it
had no effect on PI4P accumulation in UHCV cells that express full-
length HCV polyprotein (Fig. S2A and B). Thus, the inhibition of
PI4P hyper-accumulation by DCV likely results from inhibiting
NS5A conformational changes associated with PI4KA stimulation
and not via an effect on ArfGAP1.
Structural and biophysical studies suggest that DCV binds to a
dimeric state of NS5A and inﬂuences overall structure of NS5A and
Fig. 6. Biotin-tagged NS5A inhibitor pulls down NS5A from both UHCV and UNS5A
with similar efﬁciencies. (A) Structure comparison of DCV and biotin-tagged NS5A
inhibitor. (B) Huh 7.5 cells were electroporated with HCV RNA and treated with
either DMSO, DCV or biotin-tagged NS5A inhibitor and RNA is extracted 72 h post-
electroporation and HCV RNA was quantiﬁed using real time PCR using the 2ΔΔCt
method. (C) UHCV cells and UNS5A cells were induced or left uninduced for 72 h
and were either treated with DMSO or biotin-tagged NS5A inhibitor. Cells were
lysed and biotin-tagged inhibitor was precipitated using streptavidin dynabeads.
Amount of NS5A that was pulled down with the drug was detected by western
blotting.
Fig. 7. DCV does not inhibit NS5A–PI4KA interaction. UHCV cells were transduced
with retroviral particles containing HA–PI4KA. 24 h later, cells were induced or
uninduced for HCV polyprotein expression for 48 h, then treated with DMSO or
DCV (1 mM) for 24 h before lysing cells and immunoprecipitating using HA or NS5A
antibodies. The immunoprecipitated samples were blotted for HA or NS5A. The
bottom panel (input) represents crude cell lysates prior to immunoprecipitation.
hc¼heavy chain of the antibody.
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that the resistant mutants that arise reduce the afﬁnity of the drug
to NS5A (Ascher et al., 2014; Lambert et al., 2014; Bhattacharya
et al., 2014; Barakat et al., 2014; O'Boyle et al., 2013). Thus by
altering the structural integrity or ﬂexibility of NS5A, DCV might
affect not just one but multiple functions of NS5A. In addition to
inhibition of HCV assembly, genetic trans-complementation assays
using a drug-resistant NS5A suggest that DCV inhibits both cis and
trans functions of NS5A in replication (Fridell et al., 2011). Thus,
there are at least two NS5A functions in HCV RNA replication that
are inhibited by DCV. Domain I of NS5A exists in two different
conformations based on structural analysis (Love et al., 2009;
Tellinghuisen et al., 2005). Recently, Ascher et al. showed that the
DCV binds and locks NS5A Domain 1 in one of the conformations
(Ascher et al., 2014). Based on our data, this would suggest that the
NS5A conformation that DCV binds is also the conformation that
binds PI4KA. The second NS5A conformation, which DCV prevents,
would then be associated with PI4KA hyper-stimulation and
appropriate replication compartment formation. It is not clear
that PI4KA hyper-stimulation and HCV replication compartment
formation are functionally linked, since they can be uncoupled
under certain conditions (Reiss et al., 2013). In addition, PI4KA has
multiple interaction sites for NS5A (Harak et al., 2014). Thus, it is
likely that in the presence of DCV, PI4KA can still interact with
NS5A with one of the several interaction motifs but is unable to be
activated efﬁciently due to the structural constraint caused
by DCV.
Interestingly, a cyclophilin A (CypA) inhibitor was recently found
to also perturb HCV replication compartment formation (Madan
et al., 2014). CypA binds NS5A and promotes NS5A cis–trans
isomerization, which is thought to promote conformational
changes. Given the similarities between CypA inhibitors and NS5A
DAAs in terms of their effect on HCV replication compartment
formation and potential effects on NS5A conformational changes,
we propose that both likely share similarities in terms of the
mechanism of action for inhibition of HCV replication compartment
formation. NS5A DAAs may prevent CypA-dependent conforma-
tional changes in NS5A that promote replication compartment
formation and PI4KA hyper-stimulation. This common mechanism
of HCV inhibition by CypA inhibitors and NS5A DAAs highlights the
fact that cellular and viral factors involved in HCV replication
compartment formation are a rich source for antiviral drug devel-
opment (Chukkapalli and Randall, 2014).
Fig. 8. DCV-resistant mutant Y93H rescues PI4P production in DCV-treated cells. Huh 7.5 cells were infected with either WT or Y93H J6/JFH1 (2a) virus for 48 h and then
treated with either DMSO (not shown) or DCV (500pM) for 2, 6 and 24 h prior to ﬁxing and staining for PI4P and NS5A as in Fig. 3. (A) Representative images of each
condition are shown. (B) Quantiﬁcation of PI4P intensity per cell. Error bars represent standard deviation between cells. ns, not signiﬁcant; npo0.05; nnpo0.01. (C) Cells
were treated as in (A) and cell lysate was analyzed by SDS-PAGE and blotted for NS5A and Actin.
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Conclusions
In this study, we show evidence that PI4P hyper-accumulation
seen in HCV polyprotein expressing cells is drastically reduced in
DCV-treated cells. However, DCV is unable to impair early events
of the NS5A–PI4KA interaction that can occur when NS5A is
expressed alone. In addition, DCV inhibits replicase formation.
Altogether, the data are most consistent with a model wherein
DCV inhibits conformational changes in the NS5A protein or
protein complex formations that occur in the context of HCV
polyprotein expression. These NS5A conformational changes are
likely required to both stimulate PI4P hyper-accumulation and
form HCV replication compartment.
Materials and methods
Cells
U2OS osteosarcoma derived cell line with tetracycline inducible
expression of either full-length genotype 1a polyprotein (UHCV) or
NS5A alone (UNS5A) (kindly provided by Darius Moradpour) was
cultured in DMEM-high Glucose (Invitrogen Cat. No.: 11995) with
10% fetal bovine serum (FBS), 1 mg/ml Puromycin, 500 mg/ml
Geneticin and 1% Penicillin–Streptomycin (PS) along with 1 mg/
ml Tetracycline to repress HCV protein expression (Berger et al.,
2011; Moradpour et al., 1998). To induce HCV protein expression,
cells were washed 3–4 times before adding the above media
without tetracycline. Huh-7.5 and HEK 293 T cells were
maintained as previously described in DMEM containing 5% FBS,
0.1 mM non-essential amino acids and 1% PS (Berger et al., 2011).
T7 RNA polymerase expressing Huh-7.5.1. cells (T7RP cells) (kindly
provided by Andrew Tai) are maintained in DMEM with 10% FBS,
0.1 mM non-essential amino acids, 1% PS along with 1.5 mg/ml
Puromycin (Tai and Salloum, 2011).
Plasmids and viruses
pTRIP–HA–PI4KA was made by standard restriction enzyme diges-
tion and ligation by replacing PI4KA from pTRIP–PI4KA (previously
described (Berger et al., 2011)) with HA-tagged PI4KA from pEF–HA–
PI4KA. pJFHxJ6CNS2C3 (NS2/3) was previously described and is similar
to JC1 virus (Mateu et al., 2008; Pietschmann et al., 2006). pNS2/3
Y93H carrying DCV-resistant mutation in NS5A was made by PCR
mutagenesis and In-fusion HD (Clontech) based cloning. Brieﬂy NS2/3
was digested using SpeI and RsrII and the vector fragment (9000 bp)
was gel puriﬁed and used for cloning the two PCR product inserts
using In-fusion HD. Two PCR fragments were ampliﬁed fromwildtype
NS2/3 using Phusion high-ﬁdelity DNA polymerase (NEB) using
Forward Primer I: CCAGGGGTACAAAGTACTAGTGC, Reverse Primer I:
CTGGCCCTCCGTGTgGCAATTGATAGGAAAG; Forward Primer II:
CTTTCCTATCAATTGCcACACGGAGGGCCAG, Reverse Primer II: GCTCAC-
CAGGGGACGTCGGAC. The mutation inserted during PCR that changes
the genetic code for tyrosine to histidine is shown in lower case. The
ﬁnal plasmid was sequenced to ensure that no additional mutations
were inserted during PCR. Infectious genotype 2a virus stock of WT or
Y93H mutant was made by electroporating Huh-7.5 cells with either
RNA transcribed from NS2/3 or NS2/3 Y93H respectively as described
Fig. 9. PI4P and NS5A phosphorylation differences upon DCV treatment in T7RP cells. T7RP cells were transfected with NS3-5B expression plasmids containing WT, Y93H or
HIT-AAA NS5A. Four hours post-transfection, cells were treated with DMSO or DCV (500 pM or 5 nM) and 24 h post-transfection cells were ﬁxed (A) or lysed (C). (A) Cells
were treated as above and detected using indirect immunoﬂuorescence via sequential staining ﬁrst for NS5A (green) and then for PI4P (red). (B) PI4P intensity per cell is
quantiﬁed using Image J. (C) Cells were treated as above and run on an SDS-PAGE to detect phosphorylation differences in NS5A. (D) Ratio of p58/p56 NS5A bands quantiﬁed
using Image J.
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previously(Mateu et al., 2008; Randall et al., 2006). NS2/3 NS5AeYFP
was made by inserting an enhanced yellow ﬂuorescent protein (eYFP)
at the previously described site in domain III (SSMPP\widehatLEGEPG)
that allows replication of the virus (Moradpour et al., 2004). To
facilitate efﬁcient replication, as previously described, residues 2242–
2266 in NS5A domain II were deleted (Gottwein et al., 2011). Real-time
RT-PCR analysis to determine the amount of HCV RNAwas performed
as previously described (Berger et al., 2011) and the RNA was
quantiﬁed using 2ΔΔCT relative quantiﬁcation method. pTM1 vector
(kindly provided by Bernard Moss) was used to clone in NS3-5B from
pNS2/3 (genotype 2a) to express the non-structural proteins in T7RP
cells. DCV resistant NS5A mutant Y93H and PI4KA-interaction NS5A
mutant, HIT-AAA (208–210 amino acids) were made by standard PCR-
based cloning.
Chemicals and antibodies
Daclatasvir (DCV) (Selleck Chemicals) was dissolved in DMSO
and diluted in media to the ﬁnal concentration used for the assays.
Wortmannin (Sigma) was dissolved in DMSO and used at the
concentrations described in ﬁgure legends. Digitonin (Sigma) was
dissolved in PBS and made fresh before each use.
Primary antibodies used include: rabbit anti-GM130 (Abcam
Cat. No.: ab52649), mouse anti-PI4P (Echelon biosciences Cat. No:
ZP004), mouse anti-NS5A (9E10: a kind gift from Charles Rice,
Rockefeller University), mouse anti-NS5B (Enzo life sciences Cat.
No.: ALX-803-061), rabbit anti-Actin (Sigma Cat. No.: A2066), and
mouse anti-HA (Covance Cat. No.: MMS-101R). Alexaﬂuor-488
conjugated Wheat germ agglutinin (WGA) (Invitrogen) was
diluted to a 1 mg/ml stock solution in PBS.
Immunoﬂuorescence
Glass coverslips in 24-well plates were coated with 100 mg/ml
poly-L-lysine for 10 min, washed with sterile water and dried.
30,000 UHCV cells and 20,000 UNS5A cells were seeded and
induced for 72 h or for 96 h respectively before ﬁxing. For intracel-
lular PI4P staining, cells were ﬁxed in 4% paraformaldehyde,
permeabilized with 20 mM digitonin for 5 min, and quenched with
50 mM ammonium chloride for 15 min. Cells were then blocked
with 20% normal goat serum (NGS) for 30 min. All primary and
secondary antibodies were diluted in 10% NGS. When using mouse
anti-PI4P IgM in combination with mouse anti-NS5A IgG, cells were
stained ﬁrst with NS5A (1:20,000) and detected by anti-mouse IgG
Alexa Fluor 488 (1:1000) and were then further blocked and stained
for PI4P (1:200) and detected by anti-mouse IgM Alexa Fluor 594
(1:1000). When staining for NS5B in combination with NS5A, cells
were ﬁxed with 4% PFA and permeabilized with 0.1% Triton-X-100
and blocked with 20% NGS. Cells were ﬁrst stained for NS5B (1:200)
and detected using anti-mouse IgG Alexa Fluor 594 and then
stained for NS5A using Alexa Fluor-488 conjugated 9E10 (1:100)
(Invitrogen APEX antibody labeling kit). For plasma membrane
staining of PI4P, cells were ﬁrst incubated with 50 mg/ml Alexa
Fluor-488 conjugated Wheat Germ Agglutinin on ice for 5 min
before ﬁxing with 4% formaldehyde and 0.2% glutaraldehyde and
rinsing with 50 mM ammonium chloride (NH4Cl). Permeabilization,
blocking and staining were carefully performed on ice with pre-
chilled reagents as described by Hammond et al. (2009). Brieﬂy,
cells were blocked and permeabilized with Buffer A (20 mM PIPES,
pH 6.8, 137 mM NaCl, 2.7 mM KCl) containing 5% NGS, 50 mM
NH4Cl and 0.5% saponin for 45 min on ice. After a couple of rinses
with buffer A on ice, primary antibodies were applied in buffer A
with 5% NGS and 0.1% saponin for 1 h on ice. After two washes,
secondary antibody was applied in the same buffer as primary and
incubated for 45 min on ice. The cells were then washed four times
in buffer A and post-ﬁxed in 2% formaldehyde in PBS for 10 min on
ice and warmed to RT for additional 5 min and rinsed three times in
PBS containing 50 mM NH4Cl and once in distilled water before
mounting. After staining, all coverslips were mounted in ProLong
Gold anti-fade with Dapi nuclear stain (Invitrogen). Samples were
imaged using Olympus DSU spinning disc confocal microscope
equipped with Photometrics Evolve EMCCD camera. (UChicago
Microscopy core facility). Images were taken and processed using
SlideBook v5.0 software and analyzed using Image J (NIH).
Immunoprecipitation and western blotting
Immunoprecipitation of PI4KA and NS5A was performed as
previously described (Berger et al., 2011). Brieﬂy, HEK 293T cells
were transfected with pTRIP–HA–PI4KA, HIV–Gagpol and VSV
glycoprotein using Lipofectamine 2000. Supernatant containing
pTRIP–HA–PI4KA pseudoparticles was collected 48 h later and
used to transduce UHCV cells. Twenty-four hours post-transduc-
tion, cells were induced for HCV polyprotein expression or left
uninduced for a total of 48 h. Cells were treated with 250 pM DCV
or DMSO 24 h post-induction for a total of 24 h. Cells were lysed
on ice for 30 min in NP-40 lysis buffer (20 mM Tris–HCl, pH7.5,
150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 10% Glycerol supple-
mented with complete protease inhibitor cocktail tablets from
Roche), clariﬁed by centrifugation at 20,000g for 30 min. The
supernatant was mixed with M-280 sheep anti-mouse IgG dyna-
beads (Invitrogen) conjugated with either NS5A 9E10 antibody or
HA antibody to immunoprecipitate NS5A and HA–PI4KA respec-
tively. During overnight immunoprecipitation at 4 1C, DCV-treated
cells were further treated with 0.6 nM DCV. The immune-
complexes were washed three times in NP40-lysis buffer and
boiled with 1 Laemelli buffer for 5 min before loading on the
gel, along with 1% of input cell lysate and blotted for NS5A, HA–
PI4KA and Actin.
Synthesis of biotinylated NS5A inhibitor
(E)-Di-tert-butyl-2,20-(((ethene-1,2-diylbis(4,1-phenylene))bis
(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (1). To a
solution of 4,40-diaminostilbene dihydrochloride (60 mg,
0.21 mmol) in DCM (1 ml) potassium carbonate (58 mg, 0.42 mmol)
was added, and the resulting mixture was stirred at RT for 30 min.
Ethyl-2-ethoxyquinoline-1-(2H)-carboxylate (125 mg, 0.50 mmol)
and N-Boc proline (104 mg, 0.48 mmol) were added and the
mixture was stirred at RT for 6 h. The solvent was removed under
vacuum and the residue was triturated in ethyl ether. The products
were isolated by ﬁltration, washed with H2O and ethyl ether, and
dried under vacuum. The coupling product 1 was obtained as a
white solid in 95% yield (120 mg, 0.19 mmol). 1H NMR (300 MHz,
DMSO-d6): δ¼10.08 (s, 2H), 7.61–7.48 (m, 4H), 7.07 (s, 2H), 4.21–
4.09 (m, 2H), 3.34–3.28 (m, 4H), 2.33–2.12 (m, 2H), 1.98–1.70 (m,
6H), 1.38 (s, 9H), 1.25 (s, 9H), HRMS-ESI (m/z) calcd for C34H45N4O6
[M-H]þ: 605.7443, found: 605.3358. (E)-N,N0-(ethene-1,2-diylbis
(4,1-phenylene))bis(pyrrolidine-2-carboxamide) (2). TFA (0.15 ml)
was added slowly to a solution of 1 (60 mg, 0.01 mmol) in DCM
(1.4 ml). The reaction mixture was stirred at RT for 4 h. The solvent
was removed under vacuum, the residue was dissolved in ethyl
acetate (4 ml), washed with 1 M NaOH (2 ml) and brine (2 ml),
dried over Na2SO4, ﬁltered, and concentrated to afford 2 as a yellow
solid in 99% yield (39 mg, 0.09 mmol) which was further used
without puriﬁcation. 1H NMR (300 MHz, DMSO-d6): δ¼9.97 (s, 2H),
7.62 (d, J¼8.7 Hz, 2H), 7.48 (d, J¼8.4 Hz, 2H), 7.07 (s, 2H), 3.40–3.32
(m, 2H), 2.86 (t, J¼6.6 Hz, 4H), 2.10–1.99 (m, 2H), 1.98–1.62 (m, 6H),
HRMS-ESI (m/z) calcd for C24H29N4O2 [M-H]þ: 404.5127, found:
405.2305. (E)-1-(2-phenylacetyl)-N-(4-(4-(pyrrolidine-2-carboxa-
mido)styryl)phenyl)pyrrolidine-2-carboxamide (3). Triethyl amine
(0.014 ml, 0.09 mmol) was added to a solution of 2 (30 mg,
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0.07 mmol) in DCM (0.6 ml) at 0 1C. To this mixture a solution of
phenylacetylchloride (0.07 ml, 0.05 mmol) in DCM (0.1 ml) was
added and the reaction was stirred at RT for 4 h. The reaction
mixture was diluted with DCM (5 ml), washed with H2O (3 ml),
NaHCO3 (3 ml), and brine (3 ml), dried over Na2SO4, ﬁltered, and
concentrated. The crude product was puriﬁed by silica gel chroma-
tography with 5% MeOH in DCM as the eluent, affording 4 as a
white solid in 52% yield (13 mg, 0.02 mmol). 1H NMR (300 MHz,
CDCl3): δ¼7.59–7.49 (m, 10 H), 7.31–7.28 (m, 3H), 7.06 (d, J¼7.2 Hz,
2H), 4.60–4.56 (m, 1H), 4.04–3.99 (m, 1H), 3.78 (s, 2H), 3.76–3.58
(m, 4H), 3.28–3.12 (m, 2H), 2.07–1.89 (m, 6H), HRMS-ESI (m/z) calcd
for C32H35N4O3 [M-H]þ: 523.6453, found: 523.2736. (2S)-1-5-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno(Stedman, 2014; imida-
zol-4-yl)pentanoyl)-N-(4-((E)- 2-(4-((((2S)-1-(phenylacetyl)-2-pyr-
rolidinyl)carbonyl)amino)phenyl)vinyl)phenyl)-2-pyrrolidinecar-
boxamide (4). DIPEA (0.036 ml, 0.21 mmol) and biotin-NHS
(14.5 mg, 0.04 mmol) were added to a solution of 3 (22 mg,
0.04 mmol) in DMF (0.3 ml). The reaction mixture was stirred
overnight at RT and was slowly poured into vigorously stirred cold
ethyl ether (6 ml). The solid was isolated by ﬁltration, washed with
cold ethyl ether (4 ml) and dried under vacuum to afford the
product 4 as a white solid in 47% yield. 1H NMR (300 MHz,
DMSO-d6): δ¼10.04 (s, 2H), 7.94 (s, 1H), 7.59–7.48 (m, 6H), 7.29–
7.08 (m, 6H), 6.35 (d, J¼8.9 Hz, 2H), 4.45–4.06 (m, 4H), 3.69 (s, 2H),
3.66–4.40 (m, 4H), 3.15–2.99 (m, 1H), 2.87–2.76 (m, 2H), 2.64–1.90
(m, 8H), 1.70–1.20 (m, 8H), 1.10–1.07 (m, 2H), HRMS-ESI (m/z) calcd
for C42H49N6O5S [M-H]þ: 749.9407, found: 749.3520. The analytical
data is consistent with literature data (Gao et al., 2010). The
synthesis scheme is shown in Fig. S1.
Streptavidin pull-down
UHCV cells and UNS5A cells were induced or left uninduced for
72 h. Cells were treated with either DMSO or biotinylated NS5A
inhibitor (1 mM) for 16 h before lysis. Cells were lysed in NP-40
lysis buffer and biotinylated NS5 A inhibitor was precipitated using
M280-streptavidin dynabeads (Invitrogen) overnight at 4 1C and
washed four times in NP-40 lysis buffer and loaded on the gel
along with 1% cell lysate.
Statistical analysis
Student's t-test was performed to compare data sets. P-values
less than 0.05 were considered signiﬁcant.
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